Investors
We are committed to delivering our strategy and creating value for our shareholders.
Verona Pharma can make real a difference to the COPD market, believes CEO Jan-Anders Karlsson
Jan-Anders Karlsson says the recent strengthening of its management team has given Verona Pharma PLC (LON:VRP) the experience to take its respiratory disease treatment Ensifentrine to market.
Watch Jan-Anders Karlsson on Proactive Investors
Latest News
Latest Events
Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research
Paper demonstrates ensifentrine’s potential in improving lung function and quality of life symptoms
Holding(s) in Company TR-1: Standard form for notification of major holdings
LONDON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings
Verona Pharma Announces Senior Management Changes
LONDON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., has been appointed President and Chief Executive Officer (CEO) with effect from February 1, 2020.
Discover More
Verona Pharma
Investor Information
© Verona Pharma plc 2020. All rights reserved